DUBLIN, Calif., May 22 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Michael Molkentin, C.P.A., Chief Financial Officer and Corporate Secretary, and Michael V. McCullar, Ph.D., M.B.A., Vice President of Drug Discovery Operations, are scheduled to co-present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008 at The Grand Hyatt in New York.
SuperGen's presentation at FBR Capital Markets 12th Annual Spring Investor Conference is scheduled to begin at 10:30 a.m. EDT (7:30 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at www.supergen.com. A webcast replay of the presentation will be available shortly following the live event.
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
CONTACT: Timothy L. Enns, SVP, Corporate Communications & Business
Development, +1-925-560-0100, tenns@supergen.com; or Mary M. Vegh, Manager,
Investor Relations, +1-925-560-2845, mary.vegh@supergen.com
Web site: http://www.supergen.com/
